Differential prognostic impact of strong PD-L1 Expression and 18 F-FDG uptake in triple-negative breast cancer

Seo Hee Choi, Jee Suk Chang, JaSeung Koo, Jong Won Park, Joo Hyuk Sohn, Ki Chang Keum, Chang-Ok Suh, Yongbae Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. Methods: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Median follow-up duration was 53 months. Results: Strong PD-L1 expression was significantly associated with increased risk of recurrence along with tumor hypermetabolism. The systemic recurrence rate was significantly higher in the strong PD-L1 group than the weak PD-L1 group (35% vs. 11%; P=0.002); whereas there was no difference in locoregional failures (8% vs. 8%). Meanwhile, tumor hypermetabolism seemed to relate with an increase in overall recurrences (26% vs. 8%; P=0.019), not with specific type (locoregional, 9% vs. 3% [P=0.289]; systemic, 22% vs. 8% [P=0.051]). The relationship between PD-L1 expression and survival outcomes retained significance even after adjusting potential risk factors. Conclusions: PD-L1 and tumor metabolism might have role of predicting an increase in treatment failures. Especially, strong PD-L1 expression status was related to distant metastasis-dominant recurrence pattern which needs for intensive systemic therapy.

Original languageEnglish
Pages (from-to)1049-1057
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume41
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Triple Negative Breast Neoplasms
Fluorodeoxyglucose F18
Ligands
Recurrence
Neoplasms
Neoplasm Metastasis
Adjuvant Radiotherapy
Treatment Failure
Positron-Emission Tomography
Immunohistochemistry
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{9009a403d1e64362bf65882ca9f17310,
title = "Differential prognostic impact of strong PD-L1 Expression and 18 F-FDG uptake in triple-negative breast cancer",
abstract = "Objectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. Methods: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Median follow-up duration was 53 months. Results: Strong PD-L1 expression was significantly associated with increased risk of recurrence along with tumor hypermetabolism. The systemic recurrence rate was significantly higher in the strong PD-L1 group than the weak PD-L1 group (35{\%} vs. 11{\%}; P=0.002); whereas there was no difference in locoregional failures (8{\%} vs. 8{\%}). Meanwhile, tumor hypermetabolism seemed to relate with an increase in overall recurrences (26{\%} vs. 8{\%}; P=0.019), not with specific type (locoregional, 9{\%} vs. 3{\%} [P=0.289]; systemic, 22{\%} vs. 8{\%} [P=0.051]). The relationship between PD-L1 expression and survival outcomes retained significance even after adjusting potential risk factors. Conclusions: PD-L1 and tumor metabolism might have role of predicting an increase in treatment failures. Especially, strong PD-L1 expression status was related to distant metastasis-dominant recurrence pattern which needs for intensive systemic therapy.",
author = "Choi, {Seo Hee} and Chang, {Jee Suk} and JaSeung Koo and Park, {Jong Won} and Sohn, {Joo Hyuk} and Keum, {Ki Chang} and Chang-Ok Suh and Yongbae Kim",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/COC.0000000000000426",
language = "English",
volume = "41",
pages = "1049--1057",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

Differential prognostic impact of strong PD-L1 Expression and 18 F-FDG uptake in triple-negative breast cancer. / Choi, Seo Hee; Chang, Jee Suk; Koo, JaSeung; Park, Jong Won; Sohn, Joo Hyuk; Keum, Ki Chang; Suh, Chang-Ok; Kim, Yongbae.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 41, No. 11, 01.11.2018, p. 1049-1057.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential prognostic impact of strong PD-L1 Expression and 18 F-FDG uptake in triple-negative breast cancer

AU - Choi, Seo Hee

AU - Chang, Jee Suk

AU - Koo, JaSeung

AU - Park, Jong Won

AU - Sohn, Joo Hyuk

AU - Keum, Ki Chang

AU - Suh, Chang-Ok

AU - Kim, Yongbae

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Objectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. Methods: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Median follow-up duration was 53 months. Results: Strong PD-L1 expression was significantly associated with increased risk of recurrence along with tumor hypermetabolism. The systemic recurrence rate was significantly higher in the strong PD-L1 group than the weak PD-L1 group (35% vs. 11%; P=0.002); whereas there was no difference in locoregional failures (8% vs. 8%). Meanwhile, tumor hypermetabolism seemed to relate with an increase in overall recurrences (26% vs. 8%; P=0.019), not with specific type (locoregional, 9% vs. 3% [P=0.289]; systemic, 22% vs. 8% [P=0.051]). The relationship between PD-L1 expression and survival outcomes retained significance even after adjusting potential risk factors. Conclusions: PD-L1 and tumor metabolism might have role of predicting an increase in treatment failures. Especially, strong PD-L1 expression status was related to distant metastasis-dominant recurrence pattern which needs for intensive systemic therapy.

AB - Objectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. Methods: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Median follow-up duration was 53 months. Results: Strong PD-L1 expression was significantly associated with increased risk of recurrence along with tumor hypermetabolism. The systemic recurrence rate was significantly higher in the strong PD-L1 group than the weak PD-L1 group (35% vs. 11%; P=0.002); whereas there was no difference in locoregional failures (8% vs. 8%). Meanwhile, tumor hypermetabolism seemed to relate with an increase in overall recurrences (26% vs. 8%; P=0.019), not with specific type (locoregional, 9% vs. 3% [P=0.289]; systemic, 22% vs. 8% [P=0.051]). The relationship between PD-L1 expression and survival outcomes retained significance even after adjusting potential risk factors. Conclusions: PD-L1 and tumor metabolism might have role of predicting an increase in treatment failures. Especially, strong PD-L1 expression status was related to distant metastasis-dominant recurrence pattern which needs for intensive systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=85055674853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055674853&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000426

DO - 10.1097/COC.0000000000000426

M3 - Article

VL - 41

SP - 1049

EP - 1057

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 11

ER -